Is cosmetic platelet-rich plasma a drug to be regulated by the Food and Drug Administration?

Journal of Cosmetic Dermatology

Volumn 10, Issue 3, 2011, Pages 171-173

  Centeno, Christopher J ^a   Fuerst, Mitchell ^a   Faulkner, Stephen J ^a   Freeman, Michael ^a  

^a Centeno Schultz Clinic   (United States)

Author keywords

Grafting; Regulatory affairs; Safety

Indexed keywords

ARTICLE; AUTOTRANSPLANTATION; BLOOD AUTOTRANSFUSION; CELL THERAPY; COMPOSITE SKIN GRAFT; DRUG APPROVAL; DRUG CONTROL; ESTHETIC SURGERY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; MEDICAL PRACTICE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTE ACTIVATION; THROMBOCYTE RICH PLASMA;

DRUG AND NARCOTIC CONTROL; HUMANS; PLATELET-RICH PLASMA; TRANSPLANTATION, AUTOLOGOUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80052463161     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2011.00575.x     Document Type: Article

References (21)

1. Anitua E, Sanchez M, Nurden AT et al. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A 2006; 77: 285-93.
2. Sanchez M, Azofra J, Anitua E et al. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc 2003; 35: 1648-52.
3. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010; 83: 1-9.
4. Redaelli A, Romano D, Marciano A. Face and neck revitalization with platelet-rich plasma (PRP): clinical outcome in a series of 23 consecutively treated patients. J Drugs Dermatol 2010; 9: 466-72.
5. Sclafani AP. Applications of platelet-rich fibrin matrix in facial plastic surgery. Facial Plast Surg 2009; 25: 270-6.
6. Nakamura S, Ishihara M, Takikawa M et al. Platelet-rich plasma (PRP) promotes survival of fat-grafts in rats. Ann Plast Surg 2010; 65: 101-6.
7. Cervelli V, Palla L, Pascali M et al. Autologous platelet-rich plasma mixed with purified fat graft in aesthetic plastic surgery. Aesthetic Plast Surg 2009; 33: 716-21.
8. Cervelli V, Bantleon R, Kehlbach R et al. Application of platelet-rich plasma in plastic surgery: clinical and in vitro evaluation. Tissue Eng Part C Methods 2009; 15: 625-34.
9. People v. Privitera. Wests Calif Report 1977; 141: 764-74.
10. Use of approved drugs for unlabeled indications, D.o.H.a.H. Services, Ed. 1982.
11. Chaney v. Heckler, in 718 F.2d. 1983, District of Columbia Cir. p. 1174-7.
12. American Society of Clinical Oncology. Letter in reference to Docket No. 97N-484R-Establishment and Listing for Manufacturers of Human Cellular and Tissue-Based Products. Administrative Record for 21 CFR 1271. August 10.
13. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355: 1730-5.
14. Martineau I, Lacoste E, Gagnon G. Effects of calcium and thrombin on growth factor release from platelet concentrates: kinetics and regulation of endothelial cell proliferation. Biomaterials 2004; 25: 4489-502.
15. USFDA. Establishment registration and listing for manufacturers of human cellular and tissue-based products, CBER, Ed. 1988.
16. Schafer R, Bantleon R, Kehlbach R et al. Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticles. BMC Cell Biol 2010; 11: 22.
17. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-49.
18. Yang LY, Liu XM, Sun B et al. Adipose tissue-derived stromal cells express neuronal phenotypes. Chin Med J (Engl) 2004; 117: 425-9.
19. Yoshimura H, Muneta T, Nimura A et al. Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res 2007; 327: 449-62.
20. USFDA. Commerce, C.o.E.a., Federal Food, Drug, and Cosmetic Act. 2005, USFDA.
21. European Medicines Agency Committee for Medicinal Product for Human Use. Guideline on Human Cell-Based Medicinal Products. London. May 21, 2008.